Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging initial efficacy, safety and tolerability clinical data with its IMGN901 product candidate in the treatment of small-cell lung cancer (SCLC). In two early-stage clinical trials that enrolled patients whose SCLC had recurred following treatment with standard chemotherapies, IMGN901 administration achieved notable tumor shrinkage and/or sustained stable disease. The compound also demonstrated encouraging activity against other CD56-expressing (CD56+) solid tumors. These clinical data are being presented at the 13th World Conference on Lung Cancer taking place in San Francisco, CA, from July 31 to Aug. 4, 2009. Don't forget to buy zoloft online no prescription.

Investigational Cancer Drug BSI-201 Showed Clinical Benefit In 62% Of Patients With Triple-Negative Metastatic Breast Cancer
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage.

generic viagra online


News of the day
Sodexo's Training Strategy And Vocational Rehabilitation Program Recognized
Sodexo (PARIS:SW) (OTCBB:SDXAY) received two awards at the inaugural Professional Training Evening held May 25 in Paris: the "Best Training Strategy" award and the Favorites Award for "Successful vocational rehabilitation." The culmination of a 75-company competition, the event was organized jointly by France"s National Association of Human Res Directors (ANDRH), Professional Training Federation (FFP) and Association of Trainers and Training Managers (GARF).
Health Insurance

Stem Cell Lawyer Says Let Women Be Paid For Egg Donations

Last week, New York became the first state in America to allow scientists to pay women for donating their eggs for use in stem cell research, triggering further ethical debate. Professor Loane Skene of the Faculty of Law at the University of Melbourne and Deputy Chair of the high-profile Lockhart Committee on Human Cloning and Embryo Research (2005) says women should be paid for the invasive procedure. "This is not lawful in Australia but if embryo research leads to new cures, this ban may be reconsidered," Professor Skene says. "Given the invasiveness of extracting eggs for donation to medical research, it seems reasonable for women to receive some financial compensation, " she says. Professor Skene says that although other organ donation is free in Australia, typically organs are donated to a family member or friend. "It is unusual that organ donation is done for a complete stranger. For the effort of undergoing surgery to help medical research, I think it is appropriate for women to be remunerated." "We would be living in a nanny state if we said women may be exploited for being paid for the procedure," she says. "People undertake risky jobs every day. This is no different to a consenting adult who knows the risks of surgery making an informed decision." "When there is a breakthrough in stem cell research we will find this will be the impetus for new laws. It will reflect the push from scientists and government to be able to further investigate revolutionary treatments in this emerging field." "Stem cell research is going to be a very competitive field. It is still very early days." Professor Skene will outline social, ethical and regulatory issues raised by developments in stem cell research and explore legal responses in Australia and globally, at the 4th David Danks Oration at the University of Melbourne on Tuesday 7 July. WHAT Public Lecture "Recent developments in stem cell research: social, ethical and legal issues for the future" WHEN 6:00 - 7:00pm, Tuesday 7 July 2009 WHERE Sunderland Lecture Theatre, ground floor, Medical Building, corner of Grattan Street and Royal Parade, The University of Melbourne, Parkville (Melways reference: Map 2B C7) University of Melbourne


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009